Guggenheim lowered the firm’s price target on Ultragenyx (RARE) to $43 from $52 and keeps a Buy rating on the shares. The firm lowered its target to reflect challenges with ASPIRE Phase 3 with enrollment restricted to deletion patients between the ages of 4 and 17.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE: